Scholarlink

Background <p>Loeys-Dietz syndrome (LDS) is a rare multisystemic connective tissue disorder characterized by aggressive aortopathy, skeletal, craniofacial, cutaneous and gastrointestinal manifestations. It is caused by pathogenic variants in genes encoding components of the transforming growth factor-beta (TGF-β) signaling pathway, including <i>TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2</i> and <i>TGFB3</i>.</p> Main body <p>Preclinical modeling has been instrumental in elucidating LDS pathogenesis and informing therapeutic strategies. In this review, a comprehensive overview of available in vivo and in vitro models used to study LDS is presented. We critically evaluate the extent to which each model recapitulates the diverse LDS phenotypes and discuss their respective advantages and limitations. Attention is given to experimental design and variables that influence phenotype expression, including mouse genetic background, sex differences and variant-specific effects. We further synthetize insights gained from these models into the molecular and cellular mechanisms driving LDS, such as the TGF-β paradox, extracellular matrix dysregulation and immune activation. Lastly, we discuss current and emerging therapeutic strategies.</p> Conclusion <p>The models described here highlight the critical role of preclinical modeling in advancing our understanding of LDS pathophysiology and therapy, outlining key considerations for future model development and translational application.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical modeling of Loeys-Dietz syndrome: insights into mechanisms and therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Amira Bousbaa,
  • Ivanna Fedoryshchenko,
  • Ilse Luyckx,
  • Bart Loeys,
  • Aline Verstraeten

摘要

Background

Loeys-Dietz syndrome (LDS) is a rare multisystemic connective tissue disorder characterized by aggressive aortopathy, skeletal, craniofacial, cutaneous and gastrointestinal manifestations. It is caused by pathogenic variants in genes encoding components of the transforming growth factor-beta (TGF-β) signaling pathway, including TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2 and TGFB3.

Main body

Preclinical modeling has been instrumental in elucidating LDS pathogenesis and informing therapeutic strategies. In this review, a comprehensive overview of available in vivo and in vitro models used to study LDS is presented. We critically evaluate the extent to which each model recapitulates the diverse LDS phenotypes and discuss their respective advantages and limitations. Attention is given to experimental design and variables that influence phenotype expression, including mouse genetic background, sex differences and variant-specific effects. We further synthetize insights gained from these models into the molecular and cellular mechanisms driving LDS, such as the TGF-β paradox, extracellular matrix dysregulation and immune activation. Lastly, we discuss current and emerging therapeutic strategies.

Conclusion

The models described here highlight the critical role of preclinical modeling in advancing our understanding of LDS pathophysiology and therapy, outlining key considerations for future model development and translational application.

Graphical Abstract